Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PPIA | P62937 | 4/20 | 0.50 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | GCK | P35557 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206351 | 0.91 | LTA4H (0.58) | LTA4HMAPK14POLBMAPTMAPK1 | |
| SCHEMBL2385077 | 0.87 | ABCB1 (0.51) | LTA4HMAPK14POLBMAPTABCB1 | |
| SCHEMBL30887571 | 0.87 | ABCB1 (0.51) | LTA4HMAPK14POLBMAPTABCB1 | |
| SCHEMBL7237455 | 0.82 | NPC1 (0.68) | MAPTTDP1ABCB1HTR1ANPC1 | |
| SCHEMBL23723738 | 0.80 | MAPK14 (0.49) | LTA4HMAPK14POLBMAPTMAPK1 | |
| SCHEMBL30013758 | 0.80 | MAPK14 (0.49) | LTA4HMAPK14POLBMAPTMAPK1 | |
| SCHEMBL8526782 | 0.79 | LTA4H (0.66) | LTA4HMAPK14POLBMAPTMAPK1 | |
| SCHEMBL9567153 | 0.79 | CA1 (0.50) | LTA4HMAPK14POLBMAPK1PPIA | |
| SCHEMBL1573299 | 0.79 | LTA4H (0.60) | LTA4HMAPK14POLBMAPTMAPK1 | |
| SCHEMBL29940606 | 0.79 | MAPK14 (0.47) | LTA4HMAPK14POLBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-118047654-A | Process for preparing aryl halides starting from aromatic amines | 黑龙江立科新材料有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11866418-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117164499-A | Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-1268486-A2 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| CN-1332743-A | Cell adhesion-inhibiting antinflammatory compounds | ABBOTT CO (US) | 2002-01-23 | — | — | CN | disclosed |
| WO-2001074823-A2 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
| EP-0857171-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997015555-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
| CN-1139109-A | Pyridonesulfonylurea compounds, process for their production and herbicides containing them | ISHIHARA SANGYO KAISHA (JP) | 1997-01-01 | — | — | CN | disclosed |
| US-4652572-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-03-24 | — | — | US | disclosed |
| US-4547512-A | HISTAMINE H2-ANTAGONIST | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-10-15 | — | — | US | disclosed |
| US-4439437-A | 2-[2-Thiazolyl or 2-guanidino-4-thiazolyl methylthioethyl(or butyl)amino]-3-(hydroxy or carboxy)pyridines, compositions containing same and method of use | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-03-27 | — | — | US | disclosed |
| EP-0065825-A1 | Pyridine derivatives as histamine H2 antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | LTA4H 1784/4885MAPK14 4683/4885POLB 3565/4885 |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | LTA4H 420/4885MAPK14 3036/4885POLB 3620/4885 |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | LTA4H 420/4885MAPK14 3036/4885POLB 3620/4885 |
| US-11866418-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | LTA4H 420/4885MAPK14 3036/4885POLB 3620/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | LTA4H 2339/4885MAPK14 730/4885POLB 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.